Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceutical products for the diagnosis and treatment of allergic diseases in China and internationally. The company offers Changdi, a dust mine drops; Changhao, an artemisia annua pollen allergen sublingual drops; and Changdian, a dust mite skin prick diagnost… Read more
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) - Total Liabilities
Latest total liabilities as of September 2025: CN¥161.98 Million CNY
Based on the latest financial reports, Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) has total liabilities worth CN¥161.98 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd - Total Liabilities Trend (2009–2024)
This chart illustrates how Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gelex Group JSC
VN:GEX
|
Vietnam | ₫43.38 Trillion |
|
Chengdu Haoneng Tech Co Ltd
SHG:603809
|
China | CN¥3.18 Billion |
|
China Suntien Green Energy Corporation Limited
PINK:CSGEF
|
USA | $58.84 Billion |
|
Gray Television Inc
NYSE:GTN-A
|
USA | $7.63 Billion |
|
Hunan Friendship&Apollo Commercial Co Ltd
SHE:002277
|
China | CN¥7.86 Billion |
|
TOWA Corporation
F:TWA
|
Germany | €27.18 Billion |
|
Harbin Gloria Pharmaceuticals
SHE:002437
|
China | CN¥852.18 Million |
|
Nippon Light Metal Holdings Company Ltd
F:N9L
|
Germany | €293.83 Billion |
Liability Composition Analysis (2009–2024)
This chart breaks down Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.78 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (2009–2024)
The table below shows the annual total liabilities of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥250.30 Million | -3.16% |
| 2023-12-31 | CN¥258.46 Million | +51.36% |
| 2022-12-31 | CN¥170.76 Million | +26.16% |
| 2021-12-31 | CN¥135.36 Million | +76.69% |
| 2020-12-31 | CN¥76.61 Million | +0.47% |
| 2019-12-31 | CN¥76.25 Million | +22.06% |
| 2018-12-31 | CN¥62.47 Million | +32.77% |
| 2017-12-31 | CN¥47.05 Million | +13.88% |
| 2016-12-31 | CN¥41.32 Million | +44.60% |
| 2015-12-31 | CN¥28.57 Million | +60.95% |
| 2014-12-31 | CN¥17.75 Million | +47.51% |
| 2013-12-31 | CN¥12.04 Million | +23.65% |
| 2012-12-31 | CN¥9.73 Million | -50.29% |
| 2011-12-31 | CN¥19.58 Million | -2.49% |
| 2010-12-31 | CN¥20.08 Million | +111.50% |
| 2009-12-31 | CN¥9.49 Million | -- |